S. Lehenbauer-Dehm

A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines (2008)

Schmid, P., Kühnhardt, D., Kiewe, P., Lehenbauer-Dehm, S., Schippinger, W., Greil, R., ...

Background: Proteasome inhibitors are a novel class of compounds entering clinical trials as a method to increase tumour sensitivity to standard chemotherapy. This phase I/II trial was carried out to...

Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: final results of a phase II trial (2005)

Schmid, P., Krocker, J., Jehn, C., Michniewicz, K., Lehenbauer-Dehm, S., Eggemann, H., ...

Background: Combinations of anthracyclines, taxanes and gemcitabine have shown high activity in breast cancer. This trial was designed to evaluate a modified combination regimen as primary...

Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: final results of a phase II trial (2005)

Schmid, P., Krocker, J., Jehn, C., Michniewicz, K., Lehenbauer-Dehm, S., Eggemann, H., ...

Background: Combinations of anthracyclines, taxanes and gemcitabine have shown high activity in breast cancer. This trial was designed to evaluate a modified combination regimen as primary...